Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2943MR)

This product GTTS-WQ2943MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2943MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15412MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ10336MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ14257MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ4248MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ1786MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ6960MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ4522MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ5882MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW